An increasing amount of money, US$3.2 billion dollars in 2009 alone, is being spent on research and development for new products intended to address diseases prevalent in the developing world (Policy Cures 2010). Assuming that even a fraction of these funds realizes the goal of creating new health interventions, low- and middle-income countries (LMICs) will face a growing number of decisions on which new interventions to use in the coming decade.
This paper focuses on national decisions to adopt, or not, a new intervention, once it becomes available (i.e. approved by the appropriate regulatory authorities and produced in sufficient quantities by a manufacturer). Such decisions would be distinct from largely regulatory determinations to allow sales of a product through private-sector channels